chufangao/CTO huggingface dataset:
Clinical trial NCT05074394: Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
Official title: A Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal STI-2099 (COVI-DROPS™) as Treatment for COVID-19 Infection in Outpatient Adults
Acronym: US
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: to be replaced with a different protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-30
Primary completion date: 2022-11-30
Completion date: 2023-01-31
Clinical trial NCT02962102: Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
Official title: Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (ACTIVATE-AKI)
Acronym: ACTIVATE-AKI
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 150.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-04-03
Primary completion date: 2020-07-16
Completion date: 2020-08-06
Limitations and caveats: Limited sample size and AKI event rate
Plan to share individual participant data: NO
Clinical trial NCT04726592: Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Official title: Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: It has been determined that continuing with enrollments in this study is no longer justified due to the lack of significant impact on the expected outcomes.
Enrollment: 323.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-08
Primary completion date: 2024-04-10
Completion date: 2024-04-10
Clinical trial NCT04955574: Probiotic and Antibiotic Therapies in Women With Unexplained Infertility
Official title: Probiotic and Antibiotic Therapies in Women With Unexplained Infertility
Sponsor: McMaster University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Change in departmental research focus.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-01-31
Primary completion date: 2024-01-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02636270: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
Official title: Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation.
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-21
Primary completion date: 2022-10-14
Completion date: 2022-12-01
Plan to share individual participant data: YES
IPD sharing description: De-identifiable data may be shared with physician that is treating the only other two patients in the world with this genetic mutation.
IPD time frame: The participant data will be available when the treatment trial is actively ongoing. Per study protocol, the study will provide clinical updates to the participants primary Endocrinologist. Should the family request any further information be shared once the study is closed, it can be given to a physician specified by the family.
IPD access criteria: De-identifiable data may be shared with physician that is treating the only other two patients in the world with this genetic mutation.
Clinical trial NCT04189315: Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
Official title: A Phase 4, Randomized, Multicenter, Open-Label, 2-Dosage Regimen, Safety and Tolerability, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia
Acronym: REBUILD
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: R\&D portfolio review and in light of the global impact of the COVID-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Plan to share individual participant data: NO
Clinical trial NCT03259425: Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
Official title: Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: DSMC Recommendation
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-03
Primary completion date: 2018-09-21
Completion date: 2020-09-25
Clinical trial NCT01960764: Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival
Official title: Phase 1 Study of Whether Host Preconditioning Modifies Short-term Transplant Survival
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: This sub-study was not done because main study results reached significance.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2022-06-30
Completion date: 2022-12-31
Clinical trial NCT04087993: Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients
Official title: Randomised, Open Lable, Active Controlled Clinical Trial to Demonstrate Safety and Efficacy of an i.v. Administration of Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients With Elective Non-cardiac Surgery (IDA I)
Acronym: IDA-I
Sponsor: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: difficult recruitment - redesign in discussion
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-05-15
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT03935594: Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
Official title: Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars; A Randomized Controlled Double-Blinded Trial
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Intervention causing discomfort to participants
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-18
Primary completion date: 2021-05-24
Completion date: 2022-10-19
Plan to share individual participant data: NO
IPD sharing description: All reasonable efforts will be made to keep a patient's protected health information (PHI) private and confidential. Electronic records will be stored in restricted access database (Redcap, Vanderbilt) open only to the study team or on sponsor electronic databases which are password protected.
Clinical trial NCT04620746: Penicillin Allergy Testing in STD Clinics
Official title: Validate an Easy to Administer Algorithm to Define Penicillin (PCN-B-lactam) Allergy Status in Sexually Transmitted Disease (STD) Clinic Outpatients
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 284.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: YES
IPD sharing description: Blinded data set is available
IPD time frame: Data will be uploaded and provided when study is completed and analyzed. Completed May 2023
Clinical trial NCT01566695: The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Official title: A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-04-26
Primary completion date: 2019-01-25
Completion date: 2023-12-21
Baseline population: The intent-to-treat (ITT) population included all participants who were randomized, regardless of whether they received treatment or not.
Clinical trial NCT03492125: A Study of the Selective PKC-β Inhibitor MS- 553
Official title: A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: MingSight Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study is terminated due to major protocol revisions. A new study in CLL patients is planned.
Enrollment: 63.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-05-25
Primary completion date: 2023-11-28
Completion date: 2023-11-28
Clinical trial NCT01556191: Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Official title: Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Acronym: LADIE
Sponsor: Intergroupe Francophone de Cancerologie Thoracique (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 379.0 (ACTUAL)
Number of arms: 4.0
Start date: 2012-05-15
Primary completion date: 2018-05-15
Completion date: 2020-06-17
Clinical trial NCT04958044: Endoscopic Assisted Calcium Electroporation in Esophageal Cancer
Official title: Endoscopic Assisted Calcium Electroporation in Esophageal Cancer - a Safety Study
Sponsor: Rigshospitalet, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-25
Primary completion date: 2022-06-13
Completion date: 2022-06-13
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03608033: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Sponsor: Omeros Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: IA did not show positive results. Study is terminated, and in process of closing
Enrollment: 356.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-16
Primary completion date: 2023-10-16
Completion date: 2023-10-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02052908: Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Official title: A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-01-27
Primary completion date: 2019-10-25
Completion date: 2021-01-05
Clinical trial NCT04671420: Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
Official title: A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Burden Follicular Lymphoma.
Sponsor: Shanghai Henlius Biotech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: sponsor strategy decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-31
Primary completion date: 2022-04-30
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT02477540: A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia
Official title: An Open Labeled, Single-center, Phase I Study Assessing the Safety and Efficacy of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia
Sponsor: Pharmicell Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study was stopped by sponsers internal reason.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-31
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT02445248: Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Official title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Acronym: JULIET
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-07-29
Primary completion date: 2022-12-22
Completion date: 2022-12-22
Baseline population: Full analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04003155: A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Official title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Acronym: Skylight 1
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 527.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-11
Primary completion date: 2020-10-29
Completion date: 2021-08-11
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT04662073: COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
Official title: COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19
Acronym: COPPS
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment into the camostat subprotocol was halted prematurely as a result of loss of equipoise due to external findings including those related to monoclonal antibodies.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-23
Primary completion date: 2021-06-08
Completion date: 2022-03-04
Baseline population: No participants were enrolled in the placebo arm.
Limitations and caveats: This study did not meet its planned enrollment and did not achieve statistical power as specified in the protocol.
Plan to share individual participant data: NO
Clinical trial NCT03815682: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Official title: A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination With Pembrolizumab in Patients With Select Solid Tumors and Lymphomas
Sponsor: Repertoire Immune Medicines (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Development program terminated
Enrollment: 23.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-24
Primary completion date: 2022-09-07
Completion date: 2022-10-11
Plan to share individual participant data: NO
Clinical trial NCT03332355: Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Official title: (STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Sponsor: Vanquish Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Reasons
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT05593445: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Official title: A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-18
Primary completion date: 2023-09-01
Completion date: 2023-12-21
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT05945147: Ketamine and Midazolam Infusions for CRPS: Feasibility Study
Official title: Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-01
Primary completion date: 2024-04-30
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT05505539: Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
Official title: Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia: a Pilot Study
Acronym: OL_5FU
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Principal Investigator no longer with university.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-30
Primary completion date: 2023-08-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03945227: Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
Official title: A Phase II Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
Sponsor: Yonsei University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to the delay in the study shceduled, due to the start of competitive study and the approval of Durvalumab from the Ministry of Food and Drug Safety, it was judged that it was difficult to enroll subjects.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-30
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Clinical trial NCT04513652: A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
Official title: A Randomized, Double-Masked, Vehicle-Controlled, Parallel Evaluation of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution
Sponsor: American Genomics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-03
Primary completion date: 2020-09-30
Completion date: 2020-12-17
Plan to share individual participant data: NO
Clinical trial NCT03807479: Study in Patients With Chronic Leukemia
Official title: Phase 2 Clinical Trial With Ponatinib as a Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Prior First Line Tyrosine Kinase Inhibitor Treatment
Acronym: PONS
Sponsor: GWT-TUD GmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: less recruting
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-11
Primary completion date: 2023-02-28
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT02787044: INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Official title: INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Acronym: INVESTED
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 5388.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-01
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Plan to share individual participant data: YES
IPD sharing description: Data will be shared according to NIH data sharing rules
IPD time frame: Data will be available as per NIH guidelines on December 4, 2022 (2 years from the primary study publication date).
IPD access criteria: Data will be available to all qualified researchers based on the NIH BIOLINCC criteria.